# Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

> **NCT04714593** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanxi Province Cancer Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia， B-Cell

## Interventions

- **BIOLOGICAL:** CD19-CD22 CAR-T cells

## Key facts

- **NCT ID:** NCT04714593
- **Lead sponsor:** Shanxi Province Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714593, "Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04714593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*